Brind.
  1. Study results were presented in Stockholm, leading to NMPA accepting the NDA for sovleplenib, using data from Peking Union Medical College Hospital.

Jianming Xu is leading a study involving HUTCHMED (China) Limited.

1 report, 1 independent Updated Jun 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jianming Xu is leading a study involving HUTCHMED (China) Limited.

Who's involved

What this event is mainly about
Jianming Xu

Keep exploring

Part of

Study results were presented in Stockholm, leading to NMPA accepting the NDA for sovleplenib, using data from Peking Union Medical College Hospital. All 1 developments

Coverage

Newest first; wire copies grouped